NEW YORK (GenomeWeb News) - Less than two years after unveiling its initial offering of instruments, Invitrogen CEO Greg Lucier told investors during the firm’s first-quarter conference call last month that the development of small instrument systems would continue to be a focused part of Invitrogen’s growth strategy and that a transplant diagnostics system would soon hit the market.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.